Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hepatology

Volumn 59, Issue 6, 2014, Pages 2083-2091

  Kumada, Hiromitsu ^a   Suzuki, Yoshiyuki ^a   Ikeda, Kenji ^a   Toyota, Joji ^b   Karino, Yoshiyasu ^b   Chayama, Kazuaki ^c   Kawakami, Yoshiiku ^c   Ido, Akio ^d   Yamamoto, Kazuhide ^e   Takaguchi, Koichi ^f   Izumi, Namiki ^g   Koike, Kazuhiko ^h   Takehara, Tetsuo ⁱ   Kawada, Norifumi ^j   Sata, Michio ^k   Miyagoshi, Hidetaka ^l   Eley, Timothy ^m   Mcphee, Fiona ^m   Damokosh, Andrew ^m   Ishikawa, Hiroki ^l   Hughes, Eric ^m   more..

^a TORANOMON HOSPITAL   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g MUSASHINO RED CROSS HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

^j Osaka Prefecture University   (Japan)

^k KURUME UNIVERSITY   (Japan)

^l Bristol Myers KK   (Japan)

^m BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; CREATININE; DACLATASVIR; HEMOGLOBIN; INTERFERON; PEGINTERFERON; RIBAVIRIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPENDICITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BURN; CHRONIC HEPATITIS C VIRUS GENOTYPE 1B INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG WITHDRAWAL; ESOPHAGEAL VARICEAL HEMORRHAGE; ESOPHAGUS HEMORRHAGE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEART INFARCTION; HEPATITIS C; HERPES ZOSTER; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYASTHENIA GRAVIS; NEUTROPHIL; OPEN STUDY; PERIARTHRITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; THROMBOCYTE; YOUNG ADULT;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84901595218     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27113     Document Type: Article

References (21)

1. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
3. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: A 2014 update for genotype 1. Hepatol Res 2014;44(Suppl S1):59-70.
4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
6. Huang CF, Yang JF, Dai CY, Huang JF, Hou NJ, Hsieh MY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010;201:751-759.
7. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012;19:e134-142.
8. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-520.
9. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-5396.
10. Bifano M, Sevinsky H, Bedford BR, Coumbis J, Eley T, Huang SP, et al. Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects [abstract]. Hepatology 2010;52(Suppl):719A.
11. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-5396.
12. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
13. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-748.
14. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. practical discriminant function using common laboratory data. Hepatol Res 2000;18:252-266.
15. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-662.
16. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369:630-639.
17. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
18. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-232.
19. Gilead Sciences. Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients. December 18, 2013. http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients.
20. Abbvie, Inc. AbbVie completes largest phase III program of an all-oral, interferon-free therapy for the treatment of hepatitis C genotype 1. January 31, 2014. http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.